Basilard Biotech is a Southern-California-based company poised to lead a revolution in the engineering of cell-based therapies in Cell and Gene Therapy (CGT). In 2019, the company launched a disruptive gene delivery technology platform called Celletto. This novel approach to nanomechanical gene delivery has the potential to disrupt the current limitations of viral and non-viral gene delivery—a breakthrough that could facilitate better scalability and more cost-effective production of cell and gene therapies.